Observational studyBMC cardiovascular disorders2025
Analysis of postoperative atrial fibrillation and its associated factors in Morrow procedures with cardiopulmonary bypass.
Observational study in BMC cardiovascular disorders, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Incidence and Predictors of Postoperative Atrial Fibrillation Following Cardiac Surgery: A Systematic Review.Annals of cardiac anaesthesia · 2026Pooled it
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
backgroundThe factors influencing the onset of new atrial fibrillation following the Morrow procedure due to cardiopulmonary bypass (CPB) are unclear. This study investigated the CPB-related factors associated with postoperative atrial fibrillation (POAF) in patients undergoing minimally invasive ventricular septal myectomy (Morrow procedure) to optimize CPB strategies, reduce the incidence of POAF, and enhance recovery.
methodsA retrospective clinical data analysis was conducted on 139 patients who underwent minimally invasive Morrow procedures from January to December 2023. The patients were divided into two groups based on whether they developed new-onset atrial fibrillation after surgery, and a comparative study was performed. Multivariate regression analysis were used to assess factors potentially influencing POAF during CPB.
resultsFifty (36%) patients developed POAF. Comparisons between the POAF group and the non-POAF group revealed significant differences in preoperative hypertension (38.0% vs. 14.6%, p = 0.002), ischaemic cardiomyopathy (40.0% vs. 20.2%, p = 0.012), history of heart failure (44.0% vs. 22.5%, p = 0.008), age (55.16 ± 14.11 vs. 46.28 ± 14.55, p = 0.001), the preoperative systemic immune-inflammation index (SII) (418.26 ± 243.97 vs. 330.24 ± 152.89, p = 0.019), the left atrial volume index (LAVI) (36.79 ± 12.08 vs. 32.24 ± 10.78, p = 0.024), CPB time (129.80 ± 39.58 vs. 116.96 ± 28.80, p = 0.027), CPB weaning time (25.68 ± 22.56 vs. 19.49 ± 6.78, p = 0.018), rate of re-CPB (14.0% vs. 3.4%, p = 0.020), rate of ultrafast-track cardiac anesthesia (UFTCA) (78.0% vs. 98.9%, p = 0.000), and ΔSII (2874.58 ± 2865.98 vs. 1981.85 ± 1519.89, p = 0.006) (P < 0.05). All patients were discharged, but the ICU (2.07 ± 2.91 vs. 1.38 ± 0.78, p = 0.046) and postoperative hospital stays (11.84 ± 7.50 vs. 9.13 ± 2.62, p = 0.002) were significantly prolonged. The results of the multivariate logistic regression analysis indicated that the occurrence of POAF was independently associated with age (OR = 1.047, 95% CI: 1.015-1.080), ΔSII(OR = 13.317, 95% CI: 3.103-57.154) and UFTCA(OR = 0.054, 95% CI: 0.006-0.493) (p < 0.05). Additionally, the increased value of SII was independently associated with CPB weaning time (t = 2.493, p = 0.014) and age(t=-2.270, p = 0.025).
conclusionUFTCA is a protective factor against POAF. Age and ΔSII are risk factors for the occurrence of POAF after the Morrow procedure. CPB weaning time and Age are significant influencing factors of ΔSII. Implementing UFTCA and shortening the CPB weaning time are expected to lower the risk of POAF, shorten ICU and hospital stays, and enhance recovery. CLINICAL TRIAL NUMBER: Not applicable.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.